i Lambert-Eaton myasthenic syndrome (LEMS) is a uncommon, but debilitating, neuromuscular disorder that is estimated to affect 2.32 people per million in Europe 1 with a prevalence of up to 3,000 cases in the US. 2 The disease has an autoimmune etiology in which autoantibodies bind to P/Q-type voltage-gated calcium channels (VGCCs) and decrease the release of acetylcholine at the synapses affecting peripheral cholinergic neurotransmission. 3 The impaired function of the VGCCs decreases the secretion of acetylcholine and disrupts synaptic transmission at neuromuscular junctions and certain autonomic nerve terminals leading to muscular weakness and symptoms of autonomic dysfunction.
ii Neuromuscular Disorders
US NEUROLOGY
The most common clinical presentation of LEMS is proximal muscle weakness (more pronounced in the hip girdle than in the shoulder girdle) and easy fatigability. The classic triad of LEMS includes proximal leg weakness, hyporeflexia or areflexia, and cholingergic dysautonomia (dry mouth, impotence, and orthostatic hypotension). 12 Tendon reflexes are reduced or absent, but it is important to note that they may be preserved early in the course of the illness. Cranial muscles may also be involved with symptoms such as ptosis, facial weakness, dysphagia, dysarthria, and difficulty chewing. Cranial muscle weakness is usually milder and rarer than in MG and it occurs after the onset of limb-girdle weakness. Additional symptoms of autonomic dysfunction include reduced salivation, erectile dysfunction, dryness of the eyes, and reduced sweating. 13 The presence of an annoying dry mouth in patients with unexplained muscular fatigability is characteristic of LEMS. A transient improvement in muscle strength and reflexes immediately after brief exercise is classically observed in LEMS patients and is pathognomonic of LEMS.
14 Diagnosis of LEMS is based on an assessment of clinical symptoms in conjunction with electrophysiologic parameters and antibody testing.
Repetitive nerve stimulation (RNS) test is the electrophysiologic study of choice for the diagnosis of LEMS. RNS test demonstrates the characteristic so-called 'LEMS triad', including (see Figure 1 ):
• Low Compound Muscles Action Potential (CMAP) amplitude.
• Decremental responses in the low-rate (2-5 Hz) stimulation.
• Marked incremental responses (facilitation) of the CMAP amplitudes in the high-rate stimulation (HRS) (50 Hz) in the RNS test or after voluntary muscle contraction over a brief (10 second) period of time. 12 For the brief exercise test, 10-second exercise is critical. 15 A more than 100 % increase in the CMAP in the HRS or after brief exercise is almost pathognomonic of LEMS. A recent study showed that a more than 60 % increment after brief exercise or during HRS is sufficient for the diagnosis of LEMS. 12 The diagnosis of LEMS may be confirmed by radioimmunoassay of VGCC antibodies, which are believed to be the main pathogenic factors in LEMS, 16 and P/Q VGCC antibodies are detected in 85 % of patients with clinically and electrophysiologically defined LEMS. 17, 18 In seronegative LEMS patients, without detectable VGCC antibodies, the electrophysiologic findings are less pronounced. 19 Because of the high prevalence of SCLC in LEMS, it is mandatory to perform a careful tumor screening, especially in patients with a history of smoking. SCLC is usually identified within 2 years of the diagnosis of LEMS. Computed tomography (CT)-thorax scans detected most of the tumors found and was far more sensitive than chest X-rays. 20 [18F]
fluorodeoxyglucose positron emission tomography (FDG-PET) may have an additive value in tumor screening in selected cases.
The Advent of an Effective Treatment Symptomatic Treatment
A range of medications have been tried with varying success as treatments for LEMS, but due to the rarity of the condition, few randomized controlled trials (RCTs) have been conducted apart from 3,4-diaminopyridine (3,4-DAP), which has been more thoroughly investigated and is discussed in the next section.
Acetylcholinesterase Inhibitors
Pyridostigmine has been used for symptomatic treatment in more than 80 cases since 1953, when the first case of LEMS was reported.
A double-blind, placebo-controlled, crossover study found significant improvement of CMAP amplitude and muscle strength with intravenous (IV) administration of 3,4-DAP but not with pyridostigmine (see Table 1 ). 21 A minimal to moderate response was reported in five patients among more than 80 treated cases in an extensive review. 22 In a few anectodal cases, pyridostigmine alone is enough to induce a satisfactory symptomatic improvement in mild cases. Often pyridostigmine is used together with guanidine and 3,4-DAP. [23] [24] [25] [26] Guanidine Hydrochloride
The potassium channel blocker, guanidine hydrochloride, is currently the only drug approved for use in LEMS 27, 28 in the US, but was approved by the US Food and Drug Administration (FDA) prior to 1962 when only safety information was necessary for approval. Guanidine acts on the presynaptic junction and, thus, is an ideal drug for symptomatic treatment of LEMS. It was mostly studied in cases reports and has not been studied in randomized trials. Guanidine has been used in about 50 LEMS cases and clinical improvement was reported in most cases. 29 The most common side effects are gastrointestinal symptoms and distal paresthesia. The most serious, but rare, side reactions of guanidine are hematologic abnormalities and renal insufficiency, which seems to be dose related. 23 Because of these rare side reactions, guanidine is 
Immunotherapy in Lambert-Eaton Myasthenic Syndrome
Considering that LEMS is an autoimmune disorder, immunotherapy should be the main stay of treatment if symptomatic treatment fails. IV immunoglobulin (IVIG) is the only therapy in which a rigorous controlled study showed effectiveness. One randomized, double-blind, placebocontrolled study showed a significant improvement in myometric strength and a significant decline in serum VGCC antibody titers with IVIG compared with placebo in nine patients. 31 Various immunosuppressive therapies such as prednisolone, azathioprine, cyclosporin, or plasma exchange have shown efficacy in LEMS, but the proportions of patients showing improvements were limited and the effects were short-lived in plasma exchange. [32] [33] [34] [35] In LEMS patients, corticosteroids can be used when required for the disease treatment; however, immunosuppressants should be avoided before the presence of a tumor is excluded. 36 Rituximab, an anti-CD 20 antibody, is a promising agent also for LEMS, but there are few reports of its use in this disease.
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Tumor Treatment in Lambert-Eaton Myasthenic Syndrome
In patients with the paraneoplastic form of LEMS, it is critical that antitumor treatments are given to treat underlying malignancies. 38 Unlike other paraneoplastic syndromes, which are usually resistant to any therapy, LEMS is known to be consistently responsive to immunotherapy or anticancer therapy. 32 Clinical data suggest that the immune response associated with LEMS may suppress tumor activity, thus prolonging survival times of LEMS patients with cancer. 39, 40 Chemotherapeutic agents, such as vincristine, doxorubicin, and cyclophosphamide, are effective against SCLC-associated LEMS, but the proportions of patients benefiting are small. 32, 35 In a study of 16 patients with LEMS associated with smallcell carcinoma, 13 patients received specific tumor therapy and most also received pharmacologic and immunologic treatment for LEMS. 32 Seven of 11 patients surviving for more than 2 months after tumor therapy showed substantial neurologic improvement, but only one patient was in complete remission 7 years after the cancer therapy. In three of these 11 patients, improvement was only transient.
The Evidence Supporting Amifampridine (3,4-diaminopyridine) as a Treatment of Lambert-Eaton Myasthenic Syndrome
In LEMS, the most widely used treatment for symptom relief is 3,4-DAP, which was first suggested to improve muscle strength and autonomic function in a small case series of LEMS patients more than 30 years ago. 41 Amifampridine
is not yet approved for LEMS in the US and currently is only available through expanded access or compassionate use programs, compounding pharmacies or in clinical trials. Amifampridine blocks voltage-gated potassium ion channels in membranes and facilitates synaptic transmission. 42 The blocking of potassium ion channels prolongs the depolarization of nerve action potentials, thereby increasing the open-time of VGCCs and consequently the influx of calcium ions into the nerve terminal. This increased calcium influx enhances the quantal release of acetylcholine, which is calcium-dependent.
Both 4-aminopyridine (4-AP) and 3,4-DAP have been used to treat LEMS but 4-aminopyridine has proved to be less effective and has a narrow toxic to therapeutic margin, 43 with many neurologic side effects reported, including seizures. 22 Three randomized, placebo-controlled trials (RCTs) (n=7-26) compared 3,4-DAP with placebo for treating LEMS over periods up to 8 weeks (see Table 1 ). 21, [24] [25] [26] All three trials showed a significant improvement in muscle strength or quantitative MG (QMG) score, and CMAP amplitude in LEMS, providing definite evidences for effective symptomatic treatment for LEMS. In the trial of Oh et al., patients with LEMS were treated with 3,4-DAP or placebo for 3 to 8 days in a randomized, double-blind, crossover study design (n=7). 48 All the studies showed that 3,4-DAP was generally well tolerated with a favorable risk: benefit ratio. Few adverse effects were reported, and these were mild, transient, and dose-related, and included paresthesia, heat sensation, difficulty sleeping, light-headedness, and fatigue. 49 3,4-DAP can, however, increase the risk for seizure, especially in patients on high daily doses (100 mg or more) and with brain metastases. An observational, retrospective cohort study included 669 patients who were treated at a multiple sclerosis (MS) clinic in France. 50 Pyridostigmine shows poor efficacy when used alone in LEMS, but can be used to increase the efficacy and reduce the required dose of 3,4-DAP.
52
Recent and Ongoing Studies on Amifampridine in Lambert-Eaton Myasthenic Syndrome
Since the above studies were completed, an additional phase III trial and a phase II trial have been initiated to further investigate the efficacy and safety of 3,4-DAP in small populations of LEMS patients (see Table 2 ).
The studies are ongoing and results are awaited with interest. A further phase I double-blind study on 59 healthy volunteers is the first formal investigation of the cardiac safety of the amifampridine phosphate (known as a thorough QT or TQT study). This trial is completed and preliminary results indicate that the treatment at and above normal dose levels has no effect on heart rate or cardiac depolarization (Biomarin, This salt species of 3,4-DAP has been shown to have superior stability 
AEs: Peri-oral and digital paresthesias
AEs = adverse events; CMAP = compound muscle action potential; 3,4-DAP = 3,4-diaminopyridine; NDS = Neurologic Disability Score; QMG = quantitative myasthenia gravis score; RNS = repetitive nerve stimulation test; SFEMG = single-fiber electromyography; SS = subjective symptom. *Murray et al. studied a double-blind comparison between a single dose of 20 mg 3,4-DAP and 120 mg pyridostigmine in six patients. Improvement was more marked with 3,4 -DAP in five by both clinical and electrophysiologic criteria. This is not included in this table because the result was only available in abstract format. 66
v compared with the base, 53 and an oral formulation containing amifampridine phosphate, equivalent to 10 mg base, was developed.
Although the safety and efficacy of amifampridine phosphate has not been directly compared with 3,4-DAP base in a RCT, it has been shown to be essentially bioequivalent with the base preparation, 54 and has been This status can permit a fast-track New Drug Application (NDA) process. 55 The NDA filing will be supported by a substantial package of safety and efficacy data derived from 54 preclinical and six clinical trials. From these data, labeling will be approved providing adequate directions for use, along with information on the risks and benefits of the product's use. It is envisaged that amifampridine phosphate may be available for use in LEMS in the US within 2-3 years.
In December 1990, FDA granted orphan drug designation to 3,4-DAP.
However, the sponsor of that application has yet to submit an NDA for approval. While the sponsor has been providing the drug free of charge to patients under treatment and expanded access protocols for many years, such provision in the absence of NDA approval circumvents important public health requirements and limits access of patients to the drug.
Treating specialists are frequently unwilling to accept the malpractice risks associated with prescribing an unapproved product or unwilling to take on the responsibilities associated with gaining access to an investigational drug required by the FDA. Patients may themselves be unwilling or unable to travel to physicians with INDs in place to be able to gain access.
Compounding by Local Pharmacies-A Serious Concern in 3,4-diaminopyridine Prescribing
Compounded drug products are produced by the ad hoc preparation of drug doses tailored to the needs of individual patients as performed in many independent community pharmacies. 56 The practice is controversial because it involves producing a drug formulation for which safety and efficacy have not been demonstrated. Compounding requires high staff competency to ensure consistent quality, but pharmacies are not usually equipped to comply with Good Manufacturing Practice (GMP) standards, which requires drug products to have an active ingredient range limit of 95-105 % of the declared label content. 57 Compounded medications may vary significantly in dosage and absorption characteristics, with no independent check of quality or variation. This results in uncertainty of the doses supplied and raises concerns for patient therapy. 58 Compounding factors have arisen with numerous different drugs. This is illustrated in a survey of compounded drug products, including female hormones, local anesthetics, and inhalation drugs, by the FDA that found 33 % of products failed testing criteria, either due to sub-or superpotency or lack of uniformity of individual dosage units. Potency ranged from 67.5 % to 268.4 % of the amount of drug declared on the product labeling. 56, [59] [60] [61] The seriousness of the problem is illustrated by accidental overdoses of 4-AP due to pharmacy errors that resulted in life-threatening seizures or status epilepticus in patients with MS or other conditions. 60, 61 Conversely, compounding that provides an insufficient dose can result in low efficacy and even treatment failure.
The quality of compounded drug formulations is an important public health concern. Its use requires local, hospital, or other pharmacies to prepare tablets or capsules from the amifampridine base compound. 53 These are used either orally or in the preparation of solutions for IV The data from these studies indicate that compounded formulations of 3,4-DAP can vary widely and that patients may be exposed to unnecessary risks. There is a need for pharmaceutical grade oral dosage forms of amifampridine to ensure consistent efficacy and patient safety. 
Conclusions and Future Developments
LEMS is a rare but seriously disabling neuromuscular disease for which effective therapy is critical. Amifampridine (3,4-DAP) has proved to be an effective treatment of LEMS in a series of randomized studies. The tolerability has been found to be acceptable and the risk: benefit ratio was favorable.
However, the variability of 3,4-DAP found in compounded preparations from different pharmacies and the associated safety risks suggest that compounding can be problematic and that approved products available as accurately measured doses would be a more effective, safe, and reliable Data from the numerous nonclinical and more than six clinical studies evaluating the safety and efficacy of amifampridine administered as the phosphate salt will lead to proper labeling that will provide physicians adequate directions for use and to appropriately instruct both physicians and patients on its risks and benefits. n
